Arquitos Capital Management released its Q2 2025 investor letter, reporting a net return of 13.1% and year-to-date gains of 28.8% as of June 30, 2025. The firm advised clients to review statements for personalized results and check the fund’s top 5 holdings for 2025 picks. Download the investor letter for more details.

Liquidia Corporation (NASDAQ:LQDA) operates in the biopharmaceutical sector, rising by 120.85% in the last 12 months. On September 22, 2025, LQDA shares closed at $22.90 with a market cap of $1.922 billion. Arquitos Capital Management highlighted LQDA’s journey, including FDA approval for Yutrepia and stock price fluctuations.

Liquidia Corporation (NASDAQ:LQDA) saw 43 hedge funds holding positions in Q2 2025, up from 39 in the previous quarter. LQDA missed Q2 2025 earnings expectations with an EPS of $-0.49. Despite potential, AI stocks may offer greater upside with less downside risk. Check out hedge fund investor letters for more insights.

Read more at Yahoo Finance: Is it a Wise Move to Buy Liquidia Corp. (LQDA) Shares?